Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

[1]  M. Krzyzanowska,et al.  Off-label use of cancer drugs: a benchmark is established. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Gemma,et al.  F1000 highlights , 2010 .

[3]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[4]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[5]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[6]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[7]  J. Soria,et al.  From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Seiichiro Yamamoto,et al.  Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.

[9]  Francesca Molinari,et al.  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.

[10]  Jane C Weeks,et al.  Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[12]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[13]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[14]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[15]  V. Servois,et al.  Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents , 2012, British Journal of Cancer.

[16]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[17]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[18]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[19]  David Olmos,et al.  Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Gestraud,et al.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial , 2014, British Journal of Cancer.

[21]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Eggermont,et al.  Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial—Interim results. , 2013 .

[23]  L. Garraway,et al.  Attitudes of patients with cancer about personalized medicine and somatic genetic testing. , 2012, Journal of oncology practice.

[24]  Daniel V.T. Catenacci,et al.  Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.

[25]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[26]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[27]  Razelle Kurzrock,et al.  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.

[28]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.